top of page
Annogen_Logo_white.png
an_banners (6).png

SuRE™ Technology Screening services


Identification of regulatory DNA elements and non-coding genetic variants that underlie traits and diseases in humans, plants and animals.

Solutions

Cell Therapy

an_icons.png

SuRE™ screening to identify promoters for better control over the expression of your transgene.

Non-Coding Genomics

an_icons (1).png

Assay the functional impact of non-coding mutations for entire genomes or specific mutation panels.

Recombinant Protein Production

an_icons (3).png

Dedicated SuRE™ screens in specific production platforms to identify optimal promoters for increased yields.

Drug Discovery

an_icons (2).png

SuRE™ reporter libraries for monitoring of multiple pathways during compound screens.

Technology
an_banners (10).png

Our novel technology in 2 steps

The SuRE method is in essence a strategy to analyze millions of DNA elements for their activity as promoters or enhancers in a single experiment. By analyzing ~300 million DNA elements of ~300bp length, an entire human genome can be analyzed exhaustively at an approximate 30 fold coverage.


The only required input is DNA and once a SuRE library is established it can be analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant (e.g. stimulatory) conditions.

Screenshot 2020-02-17 at 14.00.51.png

1

Library Construction

We first construct a plasmid library containing millions of DNA elements. A human genome is randomly sheared, size-selected and cloned into a plasmid library that contains no promoter of its own. These plasmids contain a unique 20bp sequence referred to as a barcode which allows us to uniquely identify and follow each cloned DNA element. This library is characterized (i.e. barcodes are associated to their respective DNA element) by paired-end sequencing.

9.png

barcoded plasmid

Fragmented human genome

0.2 - 2 kb

8.png
9.png

barcoded plasmid

10.png

Plasmid library containing > 300 million DNA elements

2

Library Expression Profiling

In step 2, the plasmid library is transfected into a cell type of interest. DNA elements containing promoters or enhancers will transcribe the barcode which can now be detected in the RNA by high-throughput sequencing. By comparing these barcode frequencies with the frequencies in the plasmid library, a quantitative map of promoter and enhancer activity can be constructed for the human genome. 

Transfection plasmid library into ~1*10  cells

8

Annogen_step2.1png.png

Quantify expressed barcodes

Quantify all barcodes

('input')

Ratio

Promoter and enhancer activity for entire genome

Allogen_355.png
Annogen)greenbluebarthin.png
Team

Introducing our experts

We have a team of ten highly skilled and enthusiastic scientists and technicians dedicated to our clients projects. In addition, they work on new developments around our SuRE™ platform to ensure its continuous improvement for pharmaceutical and agricultural applications. The team is led by founder Joris van Arensbergen and biotech entrepreneur Victor Schut.

News

Recent news

sign.jpg

UPDATES

Updates - October 2023  

Annogen introduces HEK293-INDX1™ - a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production

Annogen is excited to share our latest breakthrough in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline expression and high inducibility with added stimulus.

sign.jpg

EVENTS

Events - Annogen attending BIOEurope in Munich, November 6–8, 2023

Request a partnering meeting with P. Victor Schut, CBO (victor@annogen.bio) and discuss the applications of:
- SuRE™ human promoters for cell and gene therapy
- CHO genome derived promoters for protein manufacturing, cell culture, and
- AIM™ integration site mapping for cell engineering (allogeneic, cell therapy and cell line generation).

 

sign.jpg

EVENTS

Events - Annogen attending the virtual partnering at Alliance for Regenerative Medicine, October 17-18, 2023

Annogen plays a specific role in providing its SuRE™ human promoters (cell specific and/or inducible) and AIM™ integration mapping for cell engineering (e.g. allogeneic platforms).

Looking forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. Please contact (victor@annogen.bio) to learn more about the Annogen qualified promoters and cell engineering capabilities.


 

sign.jpg

EVENTS

EVENTS -March 2023 Annogen will be attending/partnering at the upcoming Cell and Gene Meeting on the Med

Looking forward to connecting with senior executives and top stakeholders and our partnering meetings. Please reach out through the partnering system or direct (victor@annogen.bio) to learn more about the Annogen qualified promoters and cell engineering capabilities.

sign.jpg

NEWS

NEWS -March 2023 Annogen enters Contract Manufacturing market:
AIM™ services and SuRE™ promoters

AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development. 
Now it is also available to the contract manufacturing market: manufacturing virus and recombinant protein

sign.jpg

Vacancy

Annogen (Amsterdam) is recruiting a
Bioinformatician

We are looking for someone who is enthusiastic about science and has a strong desire to contribute to cutting-edge research. As a Bioinformatician at our organization, you will be responsible for analysing complex biological data sets and developing and implementing computational methods for data analysis.

sign.jpg

NEWS

PRESS RELEASE - January 2023 Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.

Annogen started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments 

sign.jpg

NEWS

PRESS RELEASE - January 2023 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

Annogen to develop multiple CNS-cell specific promoters for VectorY targets

sign.jpg

NEWS

PRESS RELEASE - December 2022 Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences

Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery

sign.jpg

NEWS

PRESS RELEASE - December 2022 Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences

Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery

sign.jpg

NEWS

PRESS RELEASE - December 2022 Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences

Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery

sign.jpg

NEWS

PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.    

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Novel approach could aid selective breeding in cattle

Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical traits, such as productivity or disease tolerance, in livestock.

The study, involving Roslin researchers and their commercial partner Annogen, will focus on identifying sites in cattle DNA linked to important genes for livestock production and welfare.

annogen.png

NEWS

NEWS – Annogen Featured in C2W

SuRE technology finds hidden gene regulation. Many diseases are determined by differences in as yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome.

Read this article by Marysa van den Berg on the C2W website.

Follow our activities on LinkedIn

  • LinkedIn - White Circle
an_banners (8).png
Contact
bottom of page